 |
|
|
| |
Final Week 48 Analysis of Cenicriviroc (CVC) Compared to Efavirenz (EFV), in Combination with Emtricitabine/Tenofovir (FTC/TDF),
in Treatment-Naïve HIV-1-Infected Adults with CCR5-Tropic Virus
(Study 652-2-202; NCT01338883)
|
| |
| |
Reported by Jules Levin
EACS 2013 Oct 16-19 Brussels, Belgium
J. Feinberg1, M. Thompson2, J. Cade3, E. DeJesus4, J. Gathe5, J. Lalezari6, A. Scarsella7, M. Saag8, J. Enejosa9, E. Lefebvre9
1University of Cincinnati, Cincinnati, OH, USA, 2AIDS Research Consortium of Atlanta, Atlanta, GA, USA, 3Nevada AIDS Research and Education Society, Las Vegas, NV, USA, 4Orlando Immunology Center, Orlando, FL, USA, 5Therapeutic Concepts, Houston, TX, USA, 6Quest Clinical Research, San Francisco, CA, USA, 7Pacific Oaks Medical Group, Beverly Hills, CA, USA, 8University of Alabama at Birmingham, Birmingham, AL, USA, 9Tobira Therapeutics Inc., San Francisco, CA, USA
|
| |
|
|
|
|
|
